Drug intelligence / Profile preview

Potenfill

Development stage: Unknown
Lead developer: Medytox
Administration: Subcutaneous

Overview

Potenfill is a cross-linked hyaluronic acid (HA) dermal filler specifically developed for male urological applications, primarily for temporary penile girth enhancement. Developed by the South Korean company BioPlus, it is designed as a minimally invasive alternative to surgical penile augmentation. The product consists of a high-viscosity hyaluronic acid gel that provides immediate structural volume upon injection into the subcutaneous layer of the penile shaft. The cross-linking technology employed in Potenfill is intended to enhance the longevity of the filler by increasing its resistance to enzymatic degradation by hyaluronidase, thereby maintaining the enhancement effect for an extended period compared to non-cross-linked formulations.

Brand names: Potenfill
Other names: Potenfill HA filler

Beyond the preview

Go deeper on Potenfill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potenfill.

Explore the full profile